Principal Investigator | Metastasis Genomics Research Group | Sheba Medical Center, Israel.
Ramat Gan, Israel
Joined November 2018
- Tweets1.7K
- Following717
- Followers231
- Likes5.2K
Pinned Tweet
๐ YOFE LAB LAUNCHES ๐
As a #newPI at Sheba Medical Center I'm building a cutting-edge research lab, addressing a critical challenge โ how to stop #Cancer #Metastasis before it spreads.
Looking for research assistants and students to join us!
Apply here: [email protected]
Remarkable. Grasping this complexity of metastatic dissemination takes some getting used to (brilliantly portrayed in fig 1).
Ever wonder how heterogeneity defines bladder cancer subtypes?
Ha and Hsieh Lab postdoctoral fellows @pushpa_itagi and Samantha Schuster @fredhutch did, leading to a deep study of bladder cancer clonality, evolution, and heterogeneity published @Nature
nature.com/articles/s41586-0โฆ
ืืชืืชื ืขืืฉืื ืขื ืขืฆืืื ืฉื @theactionnet: ืื ืื ื ืืฆืืื ื ืื ืืืืขื ืืช. ืืคืฉืจ ืืืชืื ืืื: act.zazim.org.il/petitions/fโฆ
2
114
Ido Yofe retweeted
We are thrilled to share the newest publication from our lab! In this work, @RoiBalaban & @OriMoskowitz investigated the effect of #efferocytosis on #macrophage state and function in the #TME.
science.org/doi/10.1126/sciiโฆ
Ido Yofe retweeted
In patients with stage II/III HER2-positive or triple-negative breast cancer receiving neoadjuvant therapy (NAT):
ctDNA tells the real story:
* Post-NAT ctDNA+ โ HR 8.9 (recurrence risk)
* Post-op ctDNA+ โ HR 128 (!! recurrence risk)
* ctDNAโ โ 5y IDFS 94%
Not a response marker.
A recurrence biology marker.
pCR is a snapshot.
ctDNA is the future.
๐ We now need trials testing escalation strategies in ctDNA-positive patients โ
and whether converting ctDNA to negative improves outcomes.
@OncoAlert @myESMO @ASCOPost @PTarantinoMD @Dr_Oncologista #breastcancer
ascopubs.org/doi/10.1200/JCOโฆ
Ido Yofe retweeted
Metastasis kills most cancer patients and grows from invisible seeds. How do these seeds escape from attack by immune cells? These seeds harness stress hormones!๐คฏ
โฆthanks to โฆ@nyscfโฉ โฆ@parkericiโฉ for their support. Today at โฆ@Natureโฉ nature.com/articles/s41586-0โฆ
Ido Yofe retweeted
Excited to present the first major work after starting our lab at Stanford and the Arc this year: CRISPR-All, a unified genetic perturbation language for programming any major type of genetic perturbation simultaneously, in any combination, at genome scale, in human cells.
This
โก๏ธNew from #loilab
๐ฉ๐ฉOur new study shows higher baseline tumour burden predicts poorer outcomes on #immunotherapy in metastatic #breastcancer.
๐ฉWhy this matters: maybe surveillance post early #TNBC is now ready for prime time- if ultrasensitive ctDNA can detect relapse months before imaging, we can treat at low volume, when ICI may work better. #ctDNA #LiquidBiopsy #BreastCancerAwareness
๐๐๐congrats @J_DixonDouglas ๐คฉ
@PeterMacRes @PeterMacCC @oncoalert #bcsm
thebreastonline.com/article/โฆ
1
116
Ido Yofe retweeted
ctDNA analysis of SONIA published on @NatureMedicine. 34% of the patients had high ctDNA before entering the study, and derived a PFS2 benefit from an early (first line) use of CDK4/6-inhibitors. Patients with low ctDNA, instead, derived no benefit. nature.com/articles/s41591-0โฆ
"We envision a future where MRD is not only detected but also targeted in a personalized manner, with the ultimate goal of eradicating it to improve survival rates"
๐ฏ
1
156
New research in @CCR_AACR shows the powerful clinical utility of detecting minimal residual disease in ovarian cancer patients.
Co-first author and Gynecologic Oncology fellow at @MDAndersonNews, and co-first author on this study, @AnneKniselyMD shares her thoughts
Learn more here: breakthroughcancer.org/2025/โฆ
Read the full study here: aacrjournals.org/clincancerrโฆ
Ido Yofe retweeted
The curves everybodyโs been waiting for.
First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.
We are excited to share our new study @Cancer_Cell identifying Zeb2 as a master genetic switch controlling the tumor-associated macrophage (TAM) program. Led by @FadiSheban, @TgSanPhan, @CuriousKX & @FlorianIngelfi1. (1/20)
cell.com/cancer-cell/fulltexโฆ
2
6
565
Ido Yofe retweeted
We are beyond excited to share the first publication of our lab! We highlight the role of #neutrophils in shaping a more aggressive #TME through physical interactions with #breastcancer cells. The work was led by the talented @Sandra_Cam & @OriMoskowitz ๐งตnature.com/articles/s43018-0โฆ
Ido Yofe retweeted
Highly recommended
The Yofe Lab at Sheba is looking for scientists:
๐ฅผResearch Associateย โขย PhDย &ย MSc students ๐
Our new cancer research group is focused on studying metastasis with cutting-edge tech.
Interested? Send your CV & cover letter to:
[email protected]
The Yofe Lab at Sheba is looking for scientists:
๐ฅผResearch Associateย โขย PhDย &ย MSc students ๐
Our new cancer research group is focused on studying metastasis with cutting-edge tech.
Interested? Send your CV & cover letter to:
[email protected]
Ido Yofe retweeted
ืืืืื ืืฉืจืืืืช: ืฉืืื ืืืคืก ืืืงืื ื-8 ืืขืืื!
ืืืจืื ืืจืคืืื ืฉืืื ืืืฉืื ืืืืืื ืืืืคืก ืืืงืื ื-8 ืืืืจืื ืืชื ืืืืืื ืืืืืื ืืขืืื ืฉื Newsweek โ ืืืฉื ืืื ืืืืื ืืืฆื ืืืคื ืืืขืจืืช ืืืจืืืืช ืืืฉืจืืืืช.
ืืฉื ื ืืืืจืื ื ืืฆืืื ืืชืืจ ืขืฆืื, ืืฉืืื ืืื ืืื ืืืขื ื ืืจืคืืื:
Ido Yofe retweeted
Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary brnw.ch/21wQWsx
By corresponding author and #AACRIO25 speaker Ido Amit @IdoAmitLab
